Swipe through the latest business and wealth clues with our android app

Cipla, Pulmatrix join hands to co-develop asthma drug

Pharma major Cipla on Monday said it has inked a pact with Pulmatrix Inc to co-develop and commercialize Pulmazole, a formulation for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. As per the agreement, Cipla will make an upfront payment of $22 million to Pulmatrix in exchange for assignment of all rights for Pulmazol. Thereafter, both parties will equally share costs related to the future development and commercialisation of Pulmazole, and equally share worldwide free cash flow from future sales of Pulmazole.

Read More at Moneycontrol News date : 15 Apr 2019, Monday

©2019 TheNewsClues